Therapix BioSciences, of Tel-Aviv, Israel, which is developing cannabinoid-based therapies, filed its form F-1 with the SEC in order to raise up to $12 million in an IPO. It has applied to list its American depositary shares on Nasdaq under the symbol TRPX.